<bill session="117" type="s" number="4575" updated="2022-12-29T18:48:40Z">
  <state datetime="2022-07-20">REFERRED</state>
  <status>
    <introduced datetime="2022-07-20"/>
  </status>
  <introduced datetime="2022-07-20"/>
  <titles>
    <title type="display">Right to Try Clarification Act</title>
    <title type="short" as="introduced">Right to Try Clarification Act</title>
    <title type="official" as="introduced">A bill to clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.</title>
  </titles>
  <sponsor bioguide_id="B001288"/>
  <cosponsors>
    <cosponsor bioguide_id="P000603" joined="2022-07-20"/>
  </cosponsors>
  <actions>
    <action datetime="2022-07-20">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-07-20" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSJU" name="Senate Judiciary" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="8440" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-12-21T15:54:14Z" status="Introduced in Senate">Right to Try Clarification Act

This bill specifies that investigational drugs that are provided directly to individuals from manufacturers without the need for federal regulatory approval (i.e., via the Right to Try pathway) are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).</summary>
</bill>
